From: Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
LAMA | LABA | Trial numbers | Summary of ongoing Phase II/III studies |
---|---|---|---|
Aclidinium | Formoterol | NCT01572792, NCT0143797, NCT01462942, NCT01437540, NCT01049360 | 4 Phase III studies and 1 Phase II study, examining the long-term efficacy and safety of 2 different doses of aclidinium + formoterol vs monotherapy with either component and placebo |
Glycopyrrolate | Formoterol | NCT01587079, NCT01587079 | 2 Phase II studies (both recently completed), examining efficacy of the combination vs the monotherapy components and tiotropium |
Glycopyrronium | Indacaterol | NCT01120691 (SPARK), NCT01202188 (GLEAM) (pivotal studies, both completed), NCT0171251, NCT01604278, NCT01727141, NCT01529632, NCT01709903 | 2 recently completed pivotal Phase III studies investigating efficacy and safety, exacerbations, exercise, and TDI, and 5 ongoing Phase III studies, examining safety and efficacy of combination vs placebo, monotherapy components, and salmeterol/fluticasone |
Tiotropium | Olodaterol | NCT01431274, NCT01431287 (pivotal studies), NCT01525615, NCT01533922, NCT01533935, NCT01559116, NCT01536262 | 7 Phase III studies, investigating efficacy and safety of combination vs monotherapy components and effects on exercise |
Umeclidinium (GSK573719) | Vilanterol | NCT01313637, NCT01316900, NCT01316913, NCT01313650 (pivotal studies, recently completed), NCT01716520, NCT01491802 | 6 Phase III studies (4 recently completed, 2 ongoing), focused primarily on efficacy, with other studies examining AE incidence, exercise endurance time, and exertional dyspnea |